How to Build and Maintain a Historical Site Performance Database

Introduction: The Strategic Importance of a Site Performance Repository

Feasibility evaluations are often performed in silos, with site performance data stored in spreadsheets, disconnected CTMS modules, or forgotten folders. This short-term thinking results in repetitive qualification efforts, missed insights, and increased risk during site selection. A well-structured historical site database provides sponsors and CROs with a long-term, centralized repository of investigator experience, compliance trends, and enrollment metrics across multiple trials and regions.

Whether built internally or using commercial platforms, a historical site performance database allows sponsors to identify pre-qualified sites quickly, avoid repeated mistakes, and generate inspection-ready documentation on past feasibility decisions. This article provides a step-by-step guide to creating such a database, ensuring regulatory alignment and operational efficiency.

1. Core Components of a Historical Site Database

A comprehensive database should include the following key elements:

• Site Identifiers: Site name, address, country, unique site ID, associated institution
• PI and Sub-I Information: Full CV, GCP training dates, therapeutic experience
• Trial Participation History: Protocol number, indication, phase, study start/end dates
• Performance Metrics: Enrollment vs. target, deviation rates, dropout rates, data query resolution
• Audit and Inspection History: Sponsor QA audits, regulatory findings, CAPAs
• Site Activation Timelines: Time to contract, IRB approval, SIV
• Documentation Logs: Feasibility responses, CVs, SOP checklists, training logs

Each of these should be standardized using controlled fields to ensure consistency and enable dashboard reporting or automated scoring.

2. Choosing the Right Platform and Architecture

Your site database can be built using different levels of complexity:

• Basic: Excel or Google Sheets with version control and access restriction
• Intermediate: Custom SharePoint site with filters, sorting, and form-based entries
• Advanced: Integrated with CTMS, using APIs and relational database models (e.g., PostgreSQL, Oracle)

Organizations with large global trials should aim for CTMS-level integration or data warehouse models to ensure scalability and security. Ensure that user access, audit trails, and backup processes are validated per regulatory requirements.

3. Standardizing Data Fields and Taxonomies

Consistency is critical. Each record should follow a defined structure using dropdown menus, validation rules, and unique site IDs. Suggested fields include:

This structure enables easy filtering, benchmarking, and integration with feasibility dashboards or machine learning tools.

4. Data Sources and Import Strategy

Populating your historical database requires gathering data from multiple systems:

• CTMS: Monitoring reports, visit logs, enrollment stats
• EDC: Query logs, deviation reports, visit adherence
• eTMF: Site documents, training logs, audit reports
• Regulatory systems: Inspection results, IRB correspondence
• Feasibility tools: Historical questionnaire responses

Data should be imported with metadata and timestamps. Use unique keys (e.g., protocol number + site ID) to prevent duplication. Use ETL tools or APIs to automate data pulls where possible.

5. Creating Site Scorecards and Dashboards

To extract value from the database, build visual dashboards and scoring systems. These tools can help prioritize sites based on performance and risk.

Example: Site Quality Scorecard

Sites scoring >8.0 may be automatically included in future pre-selection lists.

6. Regulatory Considerations for Site Databases

Maintaining a historical performance database has regulatory implications:

• All records must be version-controlled with full audit trails
• Data must be attributable, legible, contemporaneous, original, and accurate (ALCOA)
• Any scoring or ranking algorithms should be documented in SOPs
• Database access must be role-based with documented training
• Regulatory bodies may request to review feasibility justifications stored in the database

The database should be listed in the TMF index if used for final site decisions or monitoring plans.

7. Use Case: Building a Global Oncology Site Library

A mid-sized sponsor running global oncology trials implemented a historical site performance repository integrated with its CTMS. Over 500 sites were added over two years with 35 key performance indicators tracked. The outcome:

• 40% reduction in time spent on new feasibility cycles
• Pre-screening of high-risk sites using deviation and audit filters
• Centralized access for feasibility, monitoring, and regulatory teams
• Positive feedback from FDA inspectors during sponsor GCP audit

8. Maintenance and Governance

Maintaining a high-quality database requires ongoing governance:

• Assign database owners and access managers
• Update records after each closeout visit or audit
• Archive inactive sites after defined periods (e.g., 5 years)
• Conduct quarterly quality checks on data integrity
• Train all users on data entry standards and privacy compliance

Regular audits of the database structure and access logs should be part of the sponsor’s QMS plan.

Conclusion

Building a historical site performance database is no longer a luxury—it’s a strategic imperative for sponsors and CROs managing multiple trials. By centralizing feasibility and compliance data, sponsors can accelerate site selection, reduce operational risk, and meet growing regulatory expectations. When well-designed and properly maintained, such databases become invaluable tools across feasibility, clinical operations, QA, and regulatory functions—driving consistency, quality, and speed across the entire clinical development lifecycle.

Improving Clinical Trial Site Selection with EHR Feasibility Analysis

Clinical trial success heavily depends on selecting the right sites—those capable of recruiting the appropriate patient populations efficiently. Traditional methods often rely on site-reported estimates or historical performance. However, integrating Electronic Health Records (EHRs) into feasibility assessments provides a data-driven way to optimize site selection for clinical trials and real-world evidence (RWE) studies.

This guide explains how pharma professionals and clinical trial experts can leverage EHR feasibility analysis for precision site selection, enhancing recruitment timelines, compliance, and trial success.

Why EHR-Based Site Feasibility is Critical:

Using EHRs for site selection offers distinct advantages:

• Real-time access to de-identified patient counts
• Granular data on eligibility criteria (e.g., age, comorbidities, lab values)
• Geographic insights into patient distribution
• Fewer protocol deviations due to better patient-site matching
• Data-driven predictions of enrollment timelines

By integrating EHR analysis, trial sponsors can confidently select high-performing sites, aligning with GMP quality expectations in study execution.

Step-by-Step Guide to EHR Feasibility Analysis:

1. Define Eligibility Criteria:

   Extract structured inclusion/exclusion parameters from the trial protocol—diagnosis codes, lab thresholds, medication history, and demographic filters.

2. Map Criteria to EHR Variables:

   Convert eligibility parameters into searchable EHR fields using standard terminologies like ICD-10, LOINC, or SNOMED CT. For example, “HbA1c > 8%” can be mapped to a specific LOINC code for glycohemoglobin.

3. Query Candidate Site Databases:

   Work with sites using common data models (e.g., OMOP, PCORnet) or FHIR APIs to query de-identified patient counts who match trial criteria.

4. Evaluate Temporal Criteria:

   Include date-based logic like “diagnosed within past 6 months” or “medication use for >3 months” using EHR timestamps and structured entries.

5. Compare Sites Quantitatively:

   Rank candidate sites based on number of eligible patients, historical enrollment metrics, and EHR data quality indicators.

6. Validate with Site Teams:

   Conduct virtual site visits to confirm feasibility analysis accuracy and assess operational capacity for protocol delivery.

Standardizing your feasibility workflow with structured SOPs is essential. Refer to Pharma SOP documentation for guidance on incorporating EHR-based metrics into selection checklists.

Tools Supporting EHR-Driven Site Feasibility:

Numerous platforms assist in EHR feasibility analysis:

• TriNetX: Global network of healthcare organizations providing queryable EHR data for trial planning.
• InSite: A platform developed by AstraZeneca and partners that leverages live EHR data across academic hospitals.
• ACT Network: NIH-funded tool allowing feasibility queries across U.S. research sites.
• i2b2: Open-source analytics platform enabling EHR feasibility queries in local data warehouses.

Many of these platforms align with StabilityStudies.in standards for data protection, anonymization, and ethical oversight.

Use Case: Oncology Trial Site Optimization

In a Phase III oncology study, a sponsor needed to identify sites that could enroll rare biomarker-positive patients. By querying hospital EHRs using genomic data, only three centers in the country matched eligibility at scale. Traditional feasibility would have failed to reveal this, leading to delays and low accrual.

EHR feasibility analysis enabled pre-selection of those sites, faster IRB submissions, and front-loaded recruitment—all within validated trial timelines.

Regulatory and Ethical Considerations:

• Patient Privacy: All EHR queries must be conducted on de-identified datasets, in accordance with HIPAA, GDPR, and institutional policies.
• IRB Oversight: Some queries may require IRB review or data access approvals before execution.
• Data Traceability: Ensure audit trails for all feasibility queries as per GCP and regulatory compliance.

As per CDSCO guidelines, EHR-based selection must not bias site access, and inclusion criteria should be uniformly applied across all potential centers.

Best Practices for Sponsors and CROs:

1. Use a standardized feasibility request template across all sites
2. Pre-map your inclusion/exclusion criteria to CDM-friendly terms
3. Engage site informatics teams early in the feasibility process
4. Validate query results with actual enrollment benchmarks post-trial
5. Use feasibility metrics as key performance indicators (KPIs) in site contracts

Modern sponsors also adopt AI-driven tools that predict enrollment likelihood using EHR query results and historical site performance. These approaches reduce risk and increase ROI on trial investments.

Conclusion: Future of Site Selection is Data-Driven

EHR feasibility analysis is no longer optional—it’s a strategic enabler of trial efficiency, quality, and regulatory robustness. By embedding real-time EHR data into the feasibility process, pharma organizations can identify the right sites, reduce protocol amendments, and shorten startup timelines.

As clinical trials become more complex and competitive, data-driven site selection via EHRs is the key to sustainable success in real-world and interventional studies alike.